Design of a novel multi-epitope vaccine against Marburg virus using immunoinformatics studies

Area of Science:

• Virology
• Immunology
• Bioinformatics

Background:

• Marburg virus (MARV) is a highly contagious and virulent pathogen causing severe hemorrhagic fever.
• No approved vaccines or therapeutics exist for MARV, necessitating the development of preventive strategies.
• Current management relies on supportive care for symptom alleviation and complication prevention.

Purpose of the Study:

• To design a novel multi-epitope vaccine (MEV) against MARV utilizing immunoinformatics approaches.
• To identify and select potential epitopes from MARV proteins (VP35, VP40, glycoprotein precursor).
• To predict the vaccine candidate's immunogenicity, stability, and interaction with immune receptors in silico.

Main Methods:

• In silico immunoinformatic analysis for epitope prediction and selection.
• Design of a multi-epitope construct targeting both cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes.
• In silico evaluation of vaccine construct stability, physicochemical properties, and immune response prediction.
• Assessment of potential interactions with toll-like receptor 3 (TLR3) and β-defensin.

Main Results:

• Identified CTL and HTL epitopes predicted to cover 79.44% and 70.55% of the global population, respectively.
• The designed MEV construct demonstrated stability and acceptable physicochemical properties for expression in Escherichia coli (E. coli).
• In silico predictions indicated comprehensive humoral and cellular immune responses, including efficient interaction with TLR3 and β-defensin.

Conclusions:

• The in silico-designed MARV MEV candidate shows significant potential for eliciting robust immune responses.
• The identified epitopes offer broad population coverage, suggesting a promising avenue for MARV vaccine development.
• Further in vitro and in vivo validation studies are crucial to confirm the efficacy and safety of this MEV candidate.